Cell-Lipo

Company Overview

Snapshot

Founded in December 2022 by Ofer Barshem, Cell-Lipo operates with 1–10 employees. The company has secured funding across two rounds from one investor, PipelBiz. Cell-Lipo is developing a patent-protected device for rapid, simple, sterile, and cost-effective isolation of stem cells from fat tissue, aiming to set a new gold standard in SVF stem cell isolation.

Business overview

Cell-Lipo is a Health Tech & Life Sciences company focused on providing accessible, science-based regenerative stem cell solutions. The company's core technology integrates advanced laser-assisted liposuction with a proprietary mechanical stem cell separation method. This system is designed to enhance fat grafting and support non-aesthetic clinical applications, including orthopedics for conditions like osteoarthritis and sport injuries. Cell-Lipo's offerings serve the healthcare market, particularly providers, by developing medical devices for personalized cell therapy.

Company Intelligence Q&A

When was Cell-Lipo founded and by whom?

Cell-Lipo was founded in December 2022 by Ofer Barshem.

What is Cell-Lipo's primary focus in the Health Tech & Life Sciences sector?

Cell-Lipo focuses on personalized cell therapy, providing accessible, science-based regenerative stem cell solutions for aesthetic treatments and chronic disorders.

What is Cell-Lipo's core technology?

Cell-Lipo's technology is based on a single closed system that incorporates advanced laser-assisted liposuction and a proprietary mechanical stem cell separation technology for isolating stem cells from fat tissue.

What are the key applications of Cell-Lipo's technology?

Cell-Lipo's technology is used for enhanced fat grafting and other non-aesthetic clinical applications, including orthopedics for osteoarthritis and sport injuries.

What is the strategic advantage of Cell-Lipo's stem cell isolation method?

Cell-Lipo's method enables rapid, simple, sterile, and cost-effective isolation of stem cells from fat tissue, avoiding enzymatic effects and reducing treatment time, costs, and regulatory burdens, positioning it as a potential gold standard for SVF stem cell isolation.